Terumo Corp (TSE:4543)
円 2723.5 -71.5 (-2.56%) Market Cap: 4.04 Til Enterprise Value: 4.04 Til PE Ratio: 38.11 PB Ratio: 3.05 GF Score: 95/100

Q1 2020 Terumo Corp Earnings Call Transcript

Aug 08, 2019 / 08:30AM GMT
Release Date Price: 円1568 (+1.32%)
Naoki Muto
Olympus Terumo Biomaterials Corp. - Auditor

Starting this quarter, I, Muto, will explain our results overview.

First, the overall results. In addition to the Cardiac and Vascular Company starting out strong, spending progress was slightly delayed, resulting in a start to the fiscal year in which profit grew in double digits to exceed guidance. In revenue, even when excluding the recovery from last year's shipping delay, Cardiac and Vascular Company showed double-digit growth before FX impact, driving overall group growth to 7%. Due to slight delays in the progress of spending on SG&A, especially salaries and wages, adjusted operating profit grew 11% despite some FX impact for double-digit growth. Profit before taxes grew 26% year-on-year due to far less FX loss than the same period of the previous fiscal year.

Next slide, please. This is the variance analysis of adjusted operating profit compared to the previous fiscal year. The gross profit increment by sales increase may appear small compared to guidance of JPY 33 billion for the entire year. However, that is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot